5-HT3 Receptor Antagonist (Ramosetron) vs Loperamide for the Treatment of Low Anterior Resection Syndrome(RALARS)

Recruiting now · Not applicable

Conditions studied: LARS - Low Anterior Resection Syndrome

In brief

Safety \& Efficacy of 5-HT3 Receptor Antagonist (Ramosetron) versus Loperamide for the Treatment of Low Anterior Resection Syndrome (RALLARS): Multicenter Randomized Controlled Trial

Key facts

Study ID

NCT05577845

Run by

Seoul National University Hospital

People needed

212

Starts

2023-03-27

Expected to finish

2032-12-01

Last updated by the study team

2023-04-25

Who can join

Age: 19 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• mid and low rectal cancer (AV<15cm)
• stage II, III, preop long-course CCRT, then ileostomy repair
• about 1\~12 months after operation (no stomy)
• about 1\~6 months after ileostomy repair
• major LARS

You may not qualify if…

• recurred rectal cancer
• stage IV
• IBD
• uncontrolled preoperative fecal incontinence or constipation

Where it is running

• Seoul National University Hospital — Seoul, Jongro-gu, South Korea (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.